Anchiano Therapeutics Ltd. (ANCN)

  • Offer Price

    $11.50

  • Offer Size

    2,652,174

  • 3-Year Outlook

    Positive

  • Volatility

    High

  • First Day Turnover

    24.51%

Description

We are a clinical-stage biotechnology company committed to engineering a targeted gene therapy to improve the standard of care for early-stage bladder cancer. We have discovered and are developing a biologic agent, inodiftagene, that we believe can deliver a new treatment to patients who have options that are limited in effectiveness and problematic in toxicity. Bladder cancer is a disease that typically causes symptoms early in its course and consequently presents the patient and the treating physician with an opportunity to gain control of the malignancy. However, the limitations of existing therapies, developed in the 1970s, often result in a prolonged series of unsuccessful treatments that can end in the radical removal of the bladder.

Deal Managers

Lawyers

  • Mayer Brown LLP

Auditors

  • KPMG LLP
Investors
Pre-IPO Holdings(%)
  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins
  • 30
  • 20
  • 5
  • 18

Deal Highlights

Deal Tracker

Stock Price